SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SIGA Technologies reports strong revenue diversification and growth opportunities

SIGA Technologies delivered robust financial results in 2022, showcasing revenue diversification and positive cash flows. With a focus on TPOXX and upcoming FDA submissions, the company is poised for growth. Challenges lie in regulatory hurdles and operational complexities, but opportunities abound in US Government procurement and international sales expansion.

SIGA Technologies projects robust 2023 performance with strategic growth initiatives

SIGA Technologies is poised for a successful 2023, driven by strong financial expectations and product delivery targets. The company's focus on innovation, strategic partnerships, and market expansion positions it well for future growth. Challenges in negotiations, clinical trials, and program scalability require careful management to capitalize on emerging opportunities.

SIGA Technologies projects robust growth in 2023 amidst operational challenges

SIGA Technologies is poised for strong financial performance in the second half of 2023, with revenue expectations and operating income growth.
The company's focus on TPOXX as a key treatment for orthopoxviruses and international sales growth positions it well for future success.
While facing challenges in trial data analysis and CEO transition, SIGA has opportunities for market expansion and revenue diversification.

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agenus

Atossa Genetics

Avid Bioservices

Cocrystal Pharma

Ocugen, Inc.

Sio Gene Therapies

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appeared first on InvestorPlace.

7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts

SIGA Technologies, Inc. (SIGA) CEO Phil Gomez on Q1 2021 Results - Earnings Call Transcript

- Important for Patients Who Cannot Swallow Oral Capsules - - Important for Patients Who Cannot Swallow Oral Capsules -

SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company developing drugs for health security and infectious diseases globally with a market niche in smallpox servicing various government agencies. SIGA Technologies' pipeline consists of one core FDA-approved oral drug known as TPOXX (tecovirimat), a pipeline of 3 others based on TPOXX-administration-changed/smallpox sub-indications, and one other early-stage smallpox small-molecule formulation.

SIGA Technologies: Biodefense Pharma Unlocks New Value Abroad For TPOXX

NEW YORK, March 23, 2021 (GLOBE NEWSWIRE) -- Cipla Therapeutics, a division of Cipla USA Inc., an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as "Cipla") and SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats.

Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats

SIGA Technologies, Inc. (SIGA) CEO Phil Gomez on Q4 2020 Results - Earnings Call Transcript

-  Approximately 363,000 Courses of Oral TPOXX® Delivered to U.S. Government in 2020 –

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2020

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 4, 2021. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dr. Dennis Hruby, Chief Scientific Officer.

SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results

Second Contract by a Canadian Governmental Agency for the Procurement of Oral TPOXX

SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in a panel discussion at the Non-Conventional Threats (NCT) Asia Virtual Conference.

SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020

SIGA Technologies, Inc. (SIGA) CEO Phillip Gomez on Q3 2020 Results - Earnings Call Transcript

- Third Quarter includes Delivery of Approximately 134,000 Courses of TPOXX® to U.S. Government –

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2020

NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 5, 2020. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on November 5, 2020 Following Release of Third Quarter Financial Results

NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Public Health Agency of Canada (PHAC) has issued an advanced contract award notice (ACAN), indicating that the PHAC intends to purchase up to 33,300 courses of oral TPOXX® (tecovirimat) within five years as specified in the ACAN, with 3,700 courses to be delivered by March 31, 2021; a cumulative total of 18,500 courses to be delivered by March 31, 2023; and an additional 14,800 courses to be delivered after March 31, 2023, subject to option exercise. The ACAN is required to remain open for at least 15 days, during which time a potential alternative supplier may submit a competing Statement of Capabilities. This ACAN follows, but is separate and incremental to, the issuance in April, 2020 of a contract by the Canadian Department of National Defence (CDND) for the delivery of up to 15,325 courses of oral TPOXX.

SIGA Announces Public Health Agency of Canada Intent to Purchase Up To 33,300 Courses of Oral TPOXX®

NEW YORK, Sept.  10, 2020  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference at 8:00 a.m. ET on Thursday, September 17, 2020.

SIGA to Participate at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020

NEW YORK, Aug.  31, 2020  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, SIGA’s Chief Scientific Officer, has been named a recipient of the  2021 American Society for Microbiology (ASM) Award for Applied and Biotechnological Research . The award recognizes an outstanding scientist with distinguished research achievements in the development of products, processes and technologies that have advanced the microbial sciences.

Dr. Dennis Hruby Wins 2021 ASM Award for Applied and Biotechnological Research

SIGA Technologies' (SIGA) CEO Phil Gomez on Q2 2020 Results - Earnings Call Transcript

-  Second  Quarter includes Deliveries to SNS and First International Delivery -

SIGA Technologies, Inc. Reports Financial Results for Three and Six Months Ended June 30, 2020

NEW YORK, July  30, 2020  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 6, 2020. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on August 6, 2020 Following Release of Second Quarter Financial Results

- Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications -

SIGA Announces Marketing Authorization Filing for oral tecovirimat with the European Medicines Agency for Multiple Indications

First Deliveries of Contract Option Exercises Announced in April 2020

SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million

NEW YORK, June  15, 2020  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United States Department of Defense (DoD), via the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), has increased research and development funding to approximately $23 million in connection with the DoD contract to support work necessary to gain a potential label expansion from the U.S. Food and Drug Administration (FDA) for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox. 

SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX® 

- 2,500 Courses Delivered to the Canadian Department of National Defence -

SIGA Technologies Announces First International Delivery of Oral TPOXX®

SIGA Technologies, Inc. (SIGA) CEO Phillip Gomez on Q1 2020 Results - Earnings Call Transcript

Deliveries to Maintain National Security 

News for SIGA Technologies Stock (SIGA)